Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 1Lung Neoplasms 1Leukemia, Plasma Cell 1Gliosarcoma 1Glioblastoma 1Adenoma, Islet Cell 1

Interventions

Dexamethasone 114daratumumab 68Lenalidomide 66Bortezomib 55pomalidomide 44carfilzomib 39Cyclophosphamide 33Specimen Handling 30Calcium Dobesilate 30Biopsy 27Magnetic Resonance Spectroscopy 24belantamab mafodotin 20isatuximab 19fludarabine 17talquetamab 16iberdomide 15Melphalan 15dexamethasone acetate 13dexamethasone 21-phosphate 13auricularum 13fludarabine phosphate 11selinexor 10elotuzumab 10tocilizumab 9X-Rays 8Nivolumab 8Sirolimus 7trametinib 6Whole-Body Irradiation 6Mycophenolic Acid 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Myeloma × montanide ISA 51 × 90 days × Clear all
NCT02334865 2026-05-15

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Roswell Park Cancer Institute

Phase 1 Active not recruiting
18 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡